Huons Signs Exclusive Domestic Supply Agreement for Japanese Encephalitis Vaccine 'Imojev'
Huons has entered into an agreement to exclusively supply 'Imojev,' a Japanese encephalitis vaccine from the French pharmaceutical company Substipharm, within South Korea. Through this contract, Huons is expected to further expand its influence in the domestic vaccine market.
Imojev is a live vaccine that prevents Japanese encephalitis and is a product with proven safety that is widely used around the world. Huons stated that through this collaboration, it plans to supply vaccines more stably to domestic consumers and contribute to the improvement of public health.
Recently, Huons has been expanding its reach into various fields, including the AI-based medical device business. This exclusive vaccine supply deal is interpreted as part of a strategy to strengthen Huons' existing pharmaceutical business and secure competitiveness through partnerships with global pharmaceutical companies.
A Huons official explained that this contract will serve as an opportunity to broaden the options available in the domestic vaccine market. Moving forward, Huons intends to continue its efforts to protect patient health by introducing a variety of high-quality pharmaceuticals.